Scholars Central

Search Scholars Central

Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.

Advanced searchHide advanced search

In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:

Years

1–25 of 99 articles for Myelofibrosis

Then save them, add them to a collection or cite them together.
  1. Research article · 2017

    Myelofibrosis is a Secondary Event in JAK2 Trilinear Myeloproliferative Neoplasm (MPN) and in CALR and MPL Thrombocythemia: Implications for Novel Treatment Options of Prefibrotic MPN

    Journal of Hematology & Thromboembolic Diseases · Volume 5, Issue 5

    erythromelalgic thrombocythemia followed by myeloproliferative myeloid metaplasia of spleen and bone marrow and secondary myelofibrosis. The CALR and MPL mutated JAK2 wild type thrombocythemia complicated by…

  2. Research article · 2014

    Descriptive, Comparative Study of Filipino Myelofibrosis Patients: An Agematched Comparison of Patients on Ruxolitinib vs. Best Available Therapy

    Journal of Hematology & Thromboembolic Diseases · Volume 2, Issue 6

    Introduction: Myelofibrosis is characterized by bone marrow fibrosis, cytopenias and extramedullary hematopoiesis. Ruxolitinib is a Janus Kinase-2 inhibitor recently approved for myelofibrosis. In the Philippines, it…

  3. Research article · 10 Feb 2020

    Comparison Study between Real Life and Published Data Outcome among Myelofibrosis Patients Who are Using Ruxolitinib at King Abdulaziz Medical City-Central Region

    International Journal of Medical Research & Health Sciences · Volume 9, Issue 1

    this study is to evaluate the efficacy and safety of Ruxolitinib among Myelofibrosis patients in real life compared to published data. Methods: In this retrospective observational chart review study ... reviewed the…

  4. Research article · 2014

    WHO Clinical Molecular and Pathological (WHO-CMP) Features of Congenital MPLS505N and the Acquired MPLW515l/K Mutated Essential Thrombocythemia and Myelofibrosis

    Journal of Hematology & Thromboembolic Diseases · Volume 2, Issue 6

    ages between 2 and 76 years (mean 31 years). Eight MPLS505N mutated patients had myelofibrosis (MF) from grade MF1 in 5 to grade MF2 in 3 at ages between ... Among 15 family members 9 died from thrombosis in 3…

  5. Perspective · 30 Dec 2022

    Emerging treatment in Anemia in myelofibrosis

    Imaging in Medicine · Volume 14, Issue 12

    clonal hematologic malignancy called myelofibrosis causes progressive bone marrow fibrosis. Splenomegaly, constitutional symptoms, and anaemia are some of the clinical signs of MF. Anemia has a complex pathophysiology

  6. Other · 12 Jul 2016

    Ruxolitinib for myelofibrosis

    Clinical Investigation · Volume 2, Issue 10

    Myelofibrosis (MF), a myeloproliferative neoplasm, is a disease associated with a significant burden of symptoms, shortened survival and an array of standard treatment regimens which have historically lacked impact

  7. Conference abstract · 21 Aug 2018

    Clinical, Laboratory, Molecular and Pathobiological (CLMP) criteria for diagnosis of the Myeloproliferative Neoplasms JAK2V617F trilinear polycythemia vera (PV), JAK2 exon 12 PV and JAK2V617F, CALR or MPL mutated thrombocythemias and myelofibrosis

    advanced stages of masked PV and PV complicated by splenomegaly and secondary myelofibrosis (MF). Heterozygous JAK2 V617F mutated ET is associated with low JAK2 allele and MPN disease burden ... fibrosis. Natural…

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels